Lower-Dose drug may make stem cell transplants safer for blood cancer patients
NCT ID NCT06926595
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The trial will enroll 41 adults and give them the lower dose along with two other drugs. The goal is to see if this approach works as well as higher doses but with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cyclophosphamide (low-dose), tacrolimus, mycophenolate mofetil
- What this could lead to
- If successful, this could make stem cell transplants safer and more tolerable for patients with blood cancers by reducing severe side effects from GVHD prevention.
- What could go wrong
- This is a small, early-phase study (41 people) with no comparison group. Lower doses might not prevent GVHD as well, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Penn State Cancer Institute
RECRUITINGHershey, Pennsylvania, 17033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI platform aims to unlock Real-World cancer data on a massive scale
- Can a lung protein tame severe graft-versus-host disease?
- Blood test could tailor CMV prevention after stem cell transplants
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could a common arthritis drug shield transplant patients from a dangerous virus?
- New biologic MK-1045 targets Hard-to-Treat blood cancers